tozadenant   Click here for help

GtoPdb Ligand ID: 5611

Synonyms: SYN-115 | SYN115
PDB Ligand
Compound class: Synthetic organic
Comment: An investigational orally available and selective adenosine A2A receptor antagonist.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 115.4
Molecular weight 406.17
XLogP 1.06
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES COc1ccc(c2c1nc(s2)NC(=O)N1CCC(CC1)(C)O)N1CCOCC1
Isomeric SMILES COc1ccc(c2c1nc(s2)NC(=O)N1CCC(CC1)(C)O)N1CCOCC1
InChI InChI=1S/C19H26N4O4S/c1-19(25)5-7-23(8-6-19)18(24)21-17-20-15-14(26-2)4-3-13(16(15)28-17)22-9-11-27-12-10-22/h3-4,25H,5-12H2,1-2H3,(H,20,21,24)
No information available.
Summary of Clinical Use Click here for help
Tozadenant (SYN115) is being evaluated in Phase 3 clinical trials for the treatment of Parkinson's disease (see NCT01283594 and NCT02453386). Phase 2b results are published in [2].
Mechanism Of Action and Pharmacodynamic Effects Click here for help
The rationale for the development of tozadenant as an anti-Parkinson's drug is based on evidence that suggests that A2A receptors play an important role in regulating motor function. Antagonising the effect of endogenous adenosine at A2A receptors potentiates the effect of dopamine at D2 receptors and inhibits glutamate acivation of mGluR5 receptors. It is predicted that this mechanism of action will restore motor function in Parkinson's patients without causing disruptive dyskinesias.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01283594 Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off Phase 2/Phase 3 Interventional Biotie Therapies Inc.
NCT02453386 Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients Phase 3 Interventional Biotie Therapies Inc.